-
AstraZeneca: Yingfeifan combined chemotherapy approved in China as the first immunotherapy regimen for advanced biliary cancer patients
On November 14th, AstraZeneca announced that Infineon&Co; Reg; (English trade name: IMFINZI®, common name: Duvalizumab) has officially obtained approval from the National Drug Administration on N ...